Clinical Studies Sponsored by Rigel Pharmaceuticals

Clinical Studies where

Trial Sponsor

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis	NCT00115089		2005	2005	Interventional
‌ Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)	NCT00326339	Rheumatoid arthritis	2006	2007	Interventional
‌ Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus	NCT00752999	Systemic lupus erythematosus	2008	2010	Interventional
‌ Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP	NCT03363334	Immune thrombocytopenic purpura
‌ Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)	NCT02040623		2014	2016	Interventional
‌ To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca	NCT01900249		2013	2014	Interventional
‌ A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	NCT02076412	Immune thrombocytopenic purpura	2015	2016	Interventional
‌ Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	NCT02112838	IgA nephropathy	2014	November 12, 2018	Interventional
‌ A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	NCT04138927	‌ Warm antibody autoimmune hemolytic anemia	October 30, 2019	2024	Interventional
‌ A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA	NCT03764618	‌ Warm antibody autoimmune hemolytic anemia	April 24, 2019	April 11, 2022	Interventional
‌ A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma	NCT01591044	Asthma	2012	2013	Interventional
‌ Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)	NCT00665626	Rheumatoid arthritis	2008	2009	Interventional
‌ Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis	NCT00665925	Rheumatoid arthritis	2008	2009	Interventional
‌ A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	NCT02076399	Immune thrombocytopenic purpura	July 14, 2014	April 21, 2016	Interventional
‌ Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy	NCT02433236	IgA nephropathy	2015		Interventional
‌ Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma	NCT00798096		2009	2010	Interventional
‌ Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy	NCT04904276	ITP	May 18, 2021	2022	Observational
‌ Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)	NCT05308264		September 12, 2022	2025	Interventional
‌ A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)	NCT02612558	‌ Warm antibody autoimmune hemolytic anemia	2016	2019	Interventional
‌ Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)	NCT00706342		2007	2010	Interventional
‌ Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma	NCT00446095	Lymphoma	2007	2010	Interventional
‌ Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions	NCT01597050		2012	2013	Interventional

22 results

0 selected

22 results

0 selected